Director Mitchell E. Levinson did not stand for reelection at the Annual Meeting, however he continues to serve as the Company’s Chief Strategy Officer.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Mitchell E. Levinson departed as Director at PULSE BIOSCIENCES, INC..
Action
did not stand for reelection
Role
Director
Exact text from the filing
Director Mitchell E. Levinson did not stand for reelection at the Annual Meeting, however he continues to serve as the Company’s Chief Strategy Officer.
PULSE BIOSCIENCES, INC. shareholders approved Election of six directors to hold office until the Company's 2024 annual meeting and until their successors are duly elected and qualified. at the 2023-05-25 meeting.
Proposal
director election
Outcome
passed
Meeting
2023-05-25
Exact text from the filing
1. Election of Directors Nominee For Against Abstained Broker Non-votes Robert W. Duggan 22,304,832 1,000,283 239,290 8,561,105 Manmeet S. Soni 23,260,064 271,819 12,522 8,561,105 Shelley D. Spray 23,263,329 268,572 12,504 8,561,105 Darrin R. Uecker 23,239,193 271,552 33,660 8,561,105 Richard A. van den Broek 23,260,555 271,269 12,581 8,561,105 Mahkam Zanganeh, D.D.S. 23,259,164 272,463 12,778 8,561,105 Each director nominee was duly elected
PULSE BIOSCIENCES, INC. shareholders approved Ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-25 meeting.
Proposal
auditor ratification
Outcome
passed
Meeting
2023-05-25
Exact text from the filing
2. Ratification of Appointment of Independent Registered Public Accounting Firm For Against Abstained Broker Non-votes 31,954,248 30,787 120,475 N/A The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.